Get the Stockscreener App
6.80
0.74%
0.05
After Hours:
6.81
0.010
+0.15%
Abeona Therapeutics Inc stock is traded at $6.80, with a volume of 482.12K.
It is up +0.74% in the last 24 hours and up +18.26% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$6.75
Open:
$6.77
24h Volume:
482.12K
Relative Volume:
0.29
Market Cap:
$347.87M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.6357
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
+1.34%
1M Performance:
+18.26%
6M Performance:
+24.31%
1Y Performance:
+44.07%
1-Day Range:
$6.73
$6.935
1-Week Range:
$6.36
$6.935
52-Week Range:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.80 | 345.31M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Is Abeona Therapeutics Inc. a Top Dividend Stock to Watch in 2025Stock Portfolio Allocation Guidance for Volatile Markets - metal.it
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients - GlobeNewswire
What are the latest earnings results for Abeona Therapeutics Inc.Financial News Entry Points Backed By Experts - jammulinksnews.com
What makes Abeona Therapeutics Inc. stock price move sharplyConservative Entry for High Return Setup Backed - metal.it
What is Abeona Therapeutics Inc. company’s growth strategyMaster stock selection with insider knowledge - jammulinksnews.com
What is the dividend policy of Abeona Therapeutics Inc. stockCapitalize on market shifts before others do - jammulinksnews.com
Abeona Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowTrade With Low Risk Exposure - beatles.ru
Why Abeona Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - metal.it
How volatile is Abeona Therapeutics Inc. stock compared to the marketBuild wealth faster with consistent investment plans - jammulinksnews.com
Should I hold or sell Abeona Therapeutics Inc. stock in 2025Build wealth with high-performing stocks - jammulinksnews.com
Intrinsic Value of Abeona Therapeutics Inc. Stock: Is It Undervalued or Overvalued - metal.it
What institutional investors are buying Abeona Therapeutics Inc. stockInvest in stocks with long-term growth potential - jammulinksnews.com
Why is Abeona Therapeutics Inc. stock attracting strong analyst attentionTrack stocks with high upside potential easily - jammulinksnews.com
What analysts say about Abeona Therapeutics Inc. stockSuperior investment outcomes - PrintWeekIndia
Abeona Therapeutics Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - Autocar Professional
What drives Abeona Therapeutics Inc. stock priceFree Buy/Sell Signal Notifications - Autocar Professional
Is Abeona Therapeutics Inc. a good long term investmentExplosive earnings growth - Autocar Professional
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
Abeona Therapeutics Amends Loan Agreement with Avenue - TipRanks
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com Nigeria
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment By Investing.com - Investing.com South Africa
Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven - simplywall.st
Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update - TipRanks
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):